These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
509 related articles for article (PubMed ID: 31076851)
1. Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypes. Sharma T; Schwalbe EC; Williamson D; Sill M; Hovestadt V; Mynarek M; Rutkowski S; Robinson GW; Gajjar A; Cavalli F; Ramaswamy V; Taylor MD; Lindsey JC; Hill RM; Jäger N; Korshunov A; Hicks D; Bailey S; Kool M; Chavez L; Northcott PA; Pfister SM; Clifford SC Acta Neuropathol; 2019 Aug; 138(2):309-326. PubMed ID: 31076851 [TBL] [Abstract][Full Text] [Related]
2. Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study. Schwalbe EC; Lindsey JC; Nakjang S; Crosier S; Smith AJ; Hicks D; Rafiee G; Hill RM; Iliasova A; Stone T; Pizer B; Michalski A; Joshi A; Wharton SB; Jacques TS; Bailey S; Williamson D; Clifford SC Lancet Oncol; 2017 Jul; 18(7):958-971. PubMed ID: 28545823 [TBL] [Abstract][Full Text] [Related]
3. Desmoplastic/nodular medulloblastomas (DNMB) and medulloblastomas with extensive nodularity (MBEN) disclose similar epigenetic signatures but different transcriptional profiles. Korshunov A; Sahm F; Okonechnikov K; Ryzhova M; Stichel D; Schrimpf D; Casalini B; Sievers P; Meyer J; Zheludkova O; Golanov A; Lichter P; Jones DTW; Pfister SM; Kool M; von Deimling A Acta Neuropathol; 2019 Jun; 137(6):1003-1015. PubMed ID: 30826918 [TBL] [Abstract][Full Text] [Related]
4. Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. Waszak SM; Northcott PA; Buchhalter I; Robinson GW; Sutter C; Groebner S; Grund KB; Brugières L; Jones DTW; Pajtler KW; Morrissy AS; Kool M; Sturm D; Chavez L; Ernst A; Brabetz S; Hain M; Zichner T; Segura-Wang M; Weischenfeldt J; Rausch T; Mardin BR; Zhou X; Baciu C; Lawerenz C; Chan JA; Varlet P; Guerrini-Rousseau L; Fults DW; Grajkowska W; Hauser P; Jabado N; Ra YS; Zitterbart K; Shringarpure SS; De La Vega FM; Bustamante CD; Ng HK; Perry A; MacDonald TJ; Hernáiz Driever P; Bendel AE; Bowers DC; McCowage G; Chintagumpala MM; Cohn R; Hassall T; Fleischhack G; Eggen T; Wesenberg F; Feychting M; Lannering B; Schüz J; Johansen C; Andersen TV; Röösli M; Kuehni CE; Grotzer M; Kjaerheim K; Monoranu CM; Archer TC; Duke E; Pomeroy SL; Shelagh R; Frank S; Sumerauer D; Scheurlen W; Ryzhova MV; Milde T; Kratz CP; Samuel D; Zhang J; Solomon DA; Marra M; Eils R; Bartram CR; von Hoff K; Rutkowski S; Ramaswamy V; Gilbertson RJ; Korshunov A; Taylor MD; Lichter P; Malkin D; Gajjar A; Korbel JO; Pfister SM Lancet Oncol; 2018 Jun; 19(6):785-798. PubMed ID: 29753700 [TBL] [Abstract][Full Text] [Related]
5. Approach to molecular subgrouping of medulloblastomas: Comparison of NanoString nCounter assay versus combination of immunohistochemistry and fluorescence in-situ hybridization in resource constrained centres. Kaur K; Jha P; Pathak P; Suri V; Sharma MC; Garg A; Suri A; Sarkar C J Neurooncol; 2019 Jul; 143(3):393-403. PubMed ID: 31104222 [TBL] [Abstract][Full Text] [Related]
6. Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. Ramaswamy V; Remke M; Bouffet E; Faria CC; Perreault S; Cho YJ; Shih DJ; Luu B; Dubuc AM; Northcott PA; Schüller U; Gururangan S; McLendon R; Bigner D; Fouladi M; Ligon KL; Pomeroy SL; Dunn S; Triscott J; Jabado N; Fontebasso A; Jones DT; Kool M; Karajannis MA; Gardner SL; Zagzag D; Nunes S; Pimentel J; Mora J; Lipp E; Walter AW; Ryzhova M; Zheludkova O; Kumirova E; Alshami J; Croul SE; Rutka JT; Hawkins C; Tabori U; Codispoti KE; Packer RJ; Pfister SM; Korshunov A; Taylor MD Lancet Oncol; 2013 Nov; 14(12):1200-7. PubMed ID: 24140199 [TBL] [Abstract][Full Text] [Related]
7. Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. Ramaswamy V; Remke M; Bouffet E; Bailey S; Clifford SC; Doz F; Kool M; Dufour C; Vassal G; Milde T; Witt O; von Hoff K; Pietsch T; Northcott PA; Gajjar A; Robinson GW; Padovani L; André N; Massimino M; Pizer B; Packer R; Rutkowski S; Pfister SM; Taylor MD; Pomeroy SL Acta Neuropathol; 2016 Jun; 131(6):821-31. PubMed ID: 27040285 [TBL] [Abstract][Full Text] [Related]
8. Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. Kool M; Koster J; Bunt J; Hasselt NE; Lakeman A; van Sluis P; Troost D; Meeteren NS; Caron HN; Cloos J; Mrsić A; Ylstra B; Grajkowska W; Hartmann W; Pietsch T; Ellison D; Clifford SC; Versteeg R PLoS One; 2008 Aug; 3(8):e3088. PubMed ID: 18769486 [TBL] [Abstract][Full Text] [Related]
9. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Kool M; Korshunov A; Remke M; Jones DT; Schlanstein M; Northcott PA; Cho YJ; Koster J; Schouten-van Meeteren A; van Vuurden D; Clifford SC; Pietsch T; von Bueren AO; Rutkowski S; McCabe M; Collins VP; Bäcklund ML; Haberler C; Bourdeaut F; Delattre O; Doz F; Ellison DW; Gilbertson RJ; Pomeroy SL; Taylor MD; Lichter P; Pfister SM Acta Neuropathol; 2012 Apr; 123(4):473-84. PubMed ID: 22358457 [TBL] [Abstract][Full Text] [Related]
10. DNA methylation profiling of medulloblastoma allows robust subclassification and improved outcome prediction using formalin-fixed biopsies. Schwalbe EC; Williamson D; Lindsey JC; Hamilton D; Ryan SL; Megahed H; Garami M; Hauser P; Dembowska-Baginska B; Perek D; Northcott PA; Taylor MD; Taylor RE; Ellison DW; Bailey S; Clifford SC Acta Neuropathol; 2013 Mar; 125(3):359-71. PubMed ID: 23291781 [TBL] [Abstract][Full Text] [Related]
11. Molecular Subgrouping of Medulloblastoma: Impact Upon Research and Clinical Practice. Gupta T; Shirsat N; Jalali R Curr Pediatr Rev; 2015; 11(2):106-19. PubMed ID: 26133181 [TBL] [Abstract][Full Text] [Related]
12. A simplified approach using Taqman low-density array for medulloblastoma subgrouping. Cruzeiro GAV; Salomão KB; de Biagi CAO; Baumgartner M; Sturm D; Lira RCP; de Almeida Magalhães T; Baroni Milan M; da Silva Silveira V; Saggioro FP; de Oliveira RS; Dos Santos Klinger PH; Seidinger AL; Yunes JA; de Paula Queiroz RG; Oba-Shinjo SM; Scrideli CA; Nagahashi SMK; Tone LG; Valera ET Acta Neuropathol Commun; 2019 Mar; 7(1):33. PubMed ID: 30832734 [TBL] [Abstract][Full Text] [Related]
13. Real-time PCR assay based on the differential expression of microRNAs and protein-coding genes for molecular classification of formalin-fixed paraffin embedded medulloblastomas. Kunder R; Jalali R; Sridhar E; Moiyadi A; Goel N; Goel A; Gupta T; Krishnatry R; Kannan S; Kurkure P; Deopujari C; Shetty P; Biyani N; Korshunov A; Pfister SM; Northcott PA; Shirsat NV Neuro Oncol; 2013 Dec; 15(12):1644-51. PubMed ID: 24203893 [TBL] [Abstract][Full Text] [Related]
14. Reproducibility of the NanoString 22-gene molecular subgroup assay for improved prognostic prediction of medulloblastoma. Leal LF; Evangelista AF; de Paula FE; Caravina Almeida G; Carloni AC; Saggioro F; Stavale JN; Malheiros SMF; Mançano B; de Oliveira MA; Luu B; Neder L; Taylor MD; Reis RM Neuropathology; 2018 Oct; 38(5):475-483. PubMed ID: 30155928 [TBL] [Abstract][Full Text] [Related]
16. Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial. Goschzik T; Schwalbe EC; Hicks D; Smith A; Zur Muehlen A; Figarella-Branger D; Doz F; Rutkowski S; Lannering B; Pietsch T; Clifford SC Lancet Oncol; 2018 Dec; 19(12):1602-1616. PubMed ID: 30392813 [TBL] [Abstract][Full Text] [Related]
17. Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03). Gajjar A; Robinson GW; Smith KS; Lin T; Merchant TE; Chintagumpala M; Mahajan A; Su J; Bouffet E; Bartels U; Schechter T; Hassall T; Robertson T; Nicholls W; Gururangan S; Schroeder K; Sullivan M; Wheeler G; Hansford JR; Kellie SJ; McCowage G; Cohn R; Fisher MJ; Krasin MJ; Stewart CF; Broniscer A; Buchhalter I; Tatevossian RG; Orr BA; Neale G; Klimo P; Boop F; Srinivasan A; Pfister SM; Gilbertson RJ; Onar-Thomas A; Ellison DW; Northcott PA J Clin Oncol; 2021 Mar; 39(7):822-835. PubMed ID: 33405951 [TBL] [Abstract][Full Text] [Related]
18. Prognostic classification of pediatric medulloblastoma based on chromosome 17p loss, expression of MYCC and MYCN, and Wnt pathway activation. Park AK; Lee SJ; Phi JH; Wang KC; Kim DG; Cho BK; Haberler C; Fattet S; Dufour C; Puget S; Sainte-Rose C; Bourdeaut F; Grill J; Delattre O; Kim SK; Park WY Neuro Oncol; 2012 Feb; 14(2):203-14. PubMed ID: 22090452 [TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical and nanoString-Based Subgrouping of Clinical Medulloblastoma Samples. D'Arcy CE; Nobre LF; Arnaldo A; Ramaswamy V; Taylor MD; Naz-Hazrati L; Hawkins CE J Neuropathol Exp Neurol; 2020 Apr; 79(4):437-447. PubMed ID: 32053195 [TBL] [Abstract][Full Text] [Related]
20. Transcriptome analysis stratifies second-generation non-WNT/non-SHH medulloblastoma subgroups into clinically tractable subtypes. Korshunov A; Okonechnikov K; Schrimpf D; Tonn S; Mynarek M; Koster J; Sievers P; Milde T; Sahm F; Jones DTW; von Deimling A; Pfister SM; Kool M Acta Neuropathol; 2023 Jun; 145(6):829-842. PubMed ID: 37093271 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]